Egrifta (Tesamorelin) and Pregabalin Interaction: What Clinicians and Patients Need to Know

What Is the Interaction Between Tesamorelin and Pregabalin?

Tesamorelin and pregabalin do not compete for the same metabolic enzymes, so the interaction is not pharmacokinetic. The clinical issue is pharmacodynamic: tesamorelin raises insulin-like growth factor-1 (IGF-1) and reduces insulin sensitivity, while pregabalin carries sedation and dizziness as dose-dependent adverse effects. When both drugs are used together, sedation from pregabalin may dull a patient's perception of hypoglycemia-adjacent symptoms or delay recognition of fatigue and confusion that can accompany glucose instability.

The FDA label for tesamorelin (Egrifta SV) explicitly states that growth hormone-releasing factor analogues "may cause a transient increase in blood glucose" and instructs prescribers to monitor glucose in all patients. Egrifta SV full prescribing information is available at accessdata.fda.gov. The pregabalin label (Lyrica) lists somnolence in up to 28% of patients at 300 mg/day and 38% at 600 mg/day in clinical trials for neuropathic pain, according to the FDA-approved Lyrica prescribing information.

Why the Pharmacodynamic Overlap Matters Clinically

A patient stabilized on pregabalin 150-300 mg twice daily for HIV-related neuropathy who then starts tesamorelin 2 mg subcutaneously once daily may attribute new fatigue or cognitive slowing entirely to the pregabalin. That misattribution could delay detection of worsening insulin resistance, which is already common in HIV-positive adults on antiretroviral therapy (ART).

Data from the NCBI bookshelf entry on tesamorelin pharmacology confirm that the drug's mechanism runs entirely through the hypothalamic GHRH receptor, stimulating pituitary GH release without direct hepatic enzyme induction. See the StatPearls tesamorelin pharmacology review on NCBI. Because pregabalin is also not metabolized hepatically (it is eliminated renally, largely unchanged), there is no CYP1A2, CYP2D6, or CYP3A4 interaction to track.

Severity Classification

Most clinical decision-support systems classify this pair as a minor interaction on the basis of overlapping CNS-effect potential. The absence of a pharmacokinetic vector keeps it out of the major or contraindicated tier. That classification should not be read as "no action required." In HIV-positive patients with pre-existing metabolic syndrome, the combined physiological burden is not trivial.

Tesamorelin Pharmacology and Its Glucose Effects

Tesamorelin is a synthetic analogue of human growth hormone-releasing factor (GHRF), comprising the full 44-amino-acid sequence with a trans-3-hexenoic acid group at the N-terminus that extends its plasma half-life. The primary efficacy data for tesamorelin in HIV lipodystrophy come from two phase III trials (LIPO-010A and LIPO-010B), described in the NEJM. In those trials (combined N=816), tesamorelin 2 mg/day reduced visceral adipose tissue (VAT) by a mean of 15.2% at 26 weeks versus 1.8% with placebo (P<0.001).

GH-Axis Activation and Insulin Sensitivity

GH elevation reduces peripheral glucose uptake by antagonizing insulin at the level of the insulin receptor substrate (IRS-1) pathway. IGF-1 rises compensatorily and exerts some pro-insulin effects, but the net result in clinical practice is a modest increase in fasting glucose in a subset of patients. The Egrifta SV label reports that HbA1c increased by 0.24% in tesamorelin-treated patients versus 0.08% in placebo in the phase III program.

A 2014 analysis published in the Journal of Clinical Endocrinology and Metabolism (JCEM) examined glucose metabolism in 54 HIV-positive patients on tesamorelin and found that fasting insulin rose by 12% at 26 weeks without a statistically significant change in fasting glucose, suggesting compensated insulin resistance rather than overt hyperglycemia in most participants.

Who Is at Highest Glucose Risk

Risk stratification matters. Patients with baseline HbA1c at or above 5.7% (prediabetes range per CDC criteria), body mass index above 30 kg/m², or concurrent use of protease inhibitors (which themselves reduce insulin sensitivity) face a meaningfully higher probability of glucose excursion on tesamorelin. Adding pregabalin does not worsen glucose directly, but it does complicate symptom surveillance.

Pregabalin Pharmacology and CNS Effects

Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing neurotransmitter release. It does not bind GABA receptors directly despite its structural similarity to GABA. The drug is eliminated renally with a half-life of approximately 6 hours; renal impairment requires dose reduction per the label.

Sedation Dose-Response

In the key pregabalin trials for diabetic peripheral neuropathy cited in the FDA's Lyrica label, somnolence rates were:

• 150 mg/day: approximately 14%
• 300 mg/day: approximately 28%
• 600 mg/day: approximately 38%

These rates are higher in older adults and in patients concurrently using opioids, benzodiazepines, or other CNS depressants. HIV-positive patients often carry polypharmacy burdens that already include one or more sedating agents.

Abuse Potential and Schedule V Status

The DEA classifies pregabalin as a Schedule V controlled substance due to euphoric effects observed at supratherapeutic doses. A 2019 systematic review in PLOS ONE found that misuse rates among patients prescribed pregabalin ranged from 1% to 40% depending on population, with higher rates in patients with histories of opioid use disorder. This is clinically relevant for HIV-positive patients who may have co-occurring substance use disorders.

Renal Impairment Interplay

Because tesamorelin does not alter renal clearance, no pharmacokinetic adjustment to pregabalin is needed on the basis of co-administration alone. However, if a patient's HIV disease or ART nephrotoxicity progresses to stage 3 or greater chronic kidney disease (GFR <45 mL/min/1.73 m²), pregabalin dose reduction is required per the AAFP guidelines on pregabalin prescribing, independent of tesamorelin status.

Mechanism Summary: Why There Is No CYP Interaction

Neither tesamorelin nor pregabalin is metabolized via the cytochrome P450 system in any clinically significant way.

Tesamorelin is a peptide and undergoes proteolytic degradation, similar to other peptide hormones. It does not induce or inhibit CYP3A4, CYP2C9, CYP2C19, or P-glycoprotein at therapeutic doses, as confirmed in the Egrifta SV clinical pharmacology section.

Pregabalin is not appreciably metabolized hepatically. According to a pharmacokinetic review published in Clinical Pharmacokinetics, approximately 90% of an oral pregabalin dose is excreted unchanged in urine, with less than 2% undergoing metabolism.

This dual absence of CYP involvement means drug-interaction checkers that rely only on enzyme-based algorithms may return "no interaction" for this pair, which is accurate pharmacokinetically but incomplete from a pharmacodynamic standpoint.

Monitoring Protocol When Both Drugs Are Co-Prescribed

The following stepwise monitoring framework applies when a clinician initiates or continues tesamorelin in a patient already receiving pregabalin, or vice versa.

Baseline Assessment (Before Starting Tesamorelin)

1. Measure fasting plasma glucose and HbA1c. Document baseline IGF-1.
2. Review pregabalin dose and frequency; note any recent dose escalations that could increase CNS sedation burden.
3. Assess for existing neuropathy symptoms. Pregabalin is commonly prescribed for HIV-associated distal sensory polyneuropathy, which affects an estimated 35-50% of HIV-positive patients according to a cohort analysis in JAMA Neurology.
4. Confirm renal function (eGFR) given pregabalin's renal clearance dependency.

Monitoring at 3 Months

• Repeat fasting glucose and HbA1c.
• Ask directly whether the patient has noticed increased fatigue, confusion, or difficulty concentrating. Do not rely on spontaneous reporting; pregabalin-related cognitive blunting may suppress symptom awareness.
• Review IGF-1 to confirm tesamorelin is producing the intended GH-axis response. Target IGF-1 should be within the age- and sex-matched normal range per the Endocrine Society clinical practice guideline on GH deficiency.

Monitoring at 6 Months and Beyond

• Continue HbA1c every 6 months if glucose remains stable.
• If HbA1c rises above 6.5% on two consecutive measurements, the Egrifta SV label recommends discontinuing tesamorelin and reassessing the benefit-risk ratio.
• Reassess pregabalin necessity and dose periodically. A 2021 Cochrane review on pregabalin for neuropathic pain (Cochrane Library) found a number needed to treat (NNT) of 7.7 for 50% pain reduction at 600 mg/day, meaning a meaningful proportion of patients derive limited benefit and may tolerate dose reduction.

Patient Counseling Points

Patients taking both drugs need specific, actionable language. Abstract warnings about "monitoring glucose" do not translate into changed behavior.

Glucose Symptom Recognition

Tell patients that tesamorelin works through the GH system and may cause their blood sugar to trend higher over weeks to months, not acutely. Symptoms to watch for include increased thirst, more frequent urination, and unexplained blurred vision. These are not the same as the rapid-onset shakiness or sweating of hypoglycemia. Pregabalin does not cause hypoglycemia, so low blood sugar is not the concern here; elevated glucose is.

Sedation and Fall Risk

Pregabalin's somnolence and dizziness effects are real. Patients should avoid driving or operating heavy machinery until they know how the drug affects them, particularly after dose escalation. The combination does not create additive sedation with tesamorelin specifically, but any other CNS depressants in the regimen require the same caution.

Injection Technique and Storage for Tesamorelin

Tesamorelin is administered as a 2 mg subcutaneous injection once daily, typically in the abdomen. Proper reconstitution of Egrifta SV requires sterile water for injection, with the vial rotated (not shaken) before use. Patients should rotate injection sites to reduce lipohypertrophy risk, an irony given that the drug is prescribed to reduce lipodystrophy.

When to Call the Prescriber

Patients should contact their provider promptly if they notice any of the following:

• Fasting home glucose readings consistently above 130 mg/dL
• New or worsening swelling in the hands or feet (tesamorelin can cause fluid retention)
• Significant increase in dizziness or falls attributable to pregabalin
• Any new symptoms that could represent hypersensitivity to tesamorelin (rash, injection-site pain beyond mild erythema)

Special Populations

Patients with HIV on Antiretroviral Therapy

This is the primary population for tesamorelin. Many ART regimens, particularly older protease inhibitors such as lopinavir/ritonavir, independently worsen insulin resistance. A 2010 analysis in Clinical Infectious Diseases found that protease inhibitor use was associated with a 3- to 4-fold increase in risk of new-onset diabetes mellitus. Combining a protease inhibitor with tesamorelin's GH-mediated glucose effect and pregabalin's potential to blunt symptom awareness creates a scenario that warrants more frequent glucose monitoring, not less.

Patients with Pre-existing Diabetes

The Egrifta SV label does not list diabetes as an absolute contraindication but states that tesamorelin should be used with caution and glucose monitored more frequently in this population. A patient with type 2 diabetes on pregabalin for painful diabetic neuropathy who is also HIV-positive represents a complex case where endocrinology consultation before initiating tesamorelin is reasonable.

Older Adults

Older HIV-positive adults (age 65 and above) have higher rates of polypharmacy, reduced renal clearance (affecting pregabalin elimination), and greater fall risk from CNS sedation. The American Geriatrics Society Beers Criteria does not explicitly list pregabalin as inappropriate in older adults but does flag CNS depressants as a drug class requiring vigilance for falls and cognitive impairment.

What the FDA Labels Say About Drug Interactions

The Egrifta SV prescribing information identifies one drug interaction of specific note: drugs that are metabolized by CYP450 enzymes may have altered clearance when GH axis activity changes, because growth hormone influences hepatic enzyme expression. The label states: "Pharmacological doses of glucocorticoids may attenuate the GH-stimulating effect of tesamorelin."

Pregabalin is not in this glucocorticoid category and does not appear on the Egrifta SV interaction list, consistent with the pharmacokinetic analysis above.

The Lyrica prescribing information lists interactions primarily with CNS depressants and agents that impair renal tubular secretion. Tesamorelin does not appear on the Lyrica interaction list either. The full pregabalin label is indexed at the FDA's drug database.

Both labels should be reviewed in full at the time of co-prescribing because labeling updates may post-date this article.

Summary of Interaction Profile

| Parameter | Detail | |---|---| | Interaction type | Pharmacodynamic | | CYP involvement | None | | P-glycoprotein involvement | None | | Severity classification | Minor to moderate | | Primary risk | Masked glucose dysregulation symptoms | | Dose adjustment required | Not mandated; titrate by clinical response | | Monitoring frequency | HbA1c at baseline, 3 months, then every 6 months | | Discontinuation threshold | HbA1c above 6.5% on tesamorelin (per label) |

Clinicians prescribing both agents should document the rationale for co-use, establish a clear glucose monitoring schedule at the time of initiation, and verify that the patient can describe at least two symptoms of worsening hyperglycemia before leaving the visit.